DxS launches cancer mutation kit for K-RAS in Australia
New diagnostic assists clinicians in selecting appropriate cancer therapy for patients
DxS has announced the launch of its K-RAS cancer mutation detection kit in Australia. This follows the kit meeting the compliance standards of Australia's Therapeutic Goods Administration (TGA).
DxS' TheraScreen® K-RAS kit allows clinicians to screen patients for mutations in the K-RAS gene, which correlates with poor prognosis if patients are treated with a class of drugs called EGFR inhibitors. The gene is mutated in approximately 35-45% of metastatic colorectal cancer as well as a variety of other cancers. By using TheraScreen, clinicians will be able to determine, from the outset, which patients will not respond to targeted cancer therapies such as Vectibix® and Erbitux®.
Commenting on the announcement, Dr. Stephen Little, CEO of DxS Ltd said: "The TheraScreen kit will serve as an invaluable tool in deciding on correct treatment regimes for cancer patients and we are pleased to be able to help Australian physicians in identifying which patients will not respond to these treatments.. The recent data at ASCO highlight the importance of verifying K-RAS status before prescribing EGFR inhibitor compounds, and the growing significance of companion diagnostics."
In January this year, the TheraScreen diagnostic was launched to screen patients prior to use of Amgen's EGFR inhibitor, Vectibix, given as a monotherapy for the treatment of metastatic colorectal cancer who have failed previous therapy, following EMEA market approval. The TheraScreen K-RAS Mutation test was the first clinically validated, CE-Mark certified companion diagnostic for tumour-specific mutations in colorectal cancer.
Recent publications and data from the 2008 ASCO meeting provide consistent evidence that clinical benefit from anti-EGFR treatments are only observed in patients with non-mutated K-RAS genes. In Europe, the EMEA has restricted the use of both Vectibix and Erbitux to patients with metastatic colorectal cancer who express non-mutated K-RAS.
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
